Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADRONASDAQ:AMAGNASDAQ:GEMPNASDAQ:LXRXNASDAQ:STML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsAMAGAMAG Pharmaceuticals$13.75$13.74$4.41▼$13.80$477.47M0.89950,664 shsN/AGEMPGemphire Therapeutics$0.65-2.1%$4.97$0.24▼$1.49$9.64M2.82127,174 shs48,968 shsLXRXLexicon Pharmaceuticals$0.91-0.6%$0.71$0.28▼$2.45$331.09M1.136.84 million shs1.65 million shsSTMLStemline Therapeutics$11.83$11.83$3.21▼$18.22$621.21M1.781.52 million shs1,084 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%AMAGAMAG Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GEMPGemphire Therapeutics+1.82%-2.58%+1.12%-56.75%-85.86%LXRXLexicon Pharmaceuticals-0.64%-2.08%+43.99%+117.24%-45.18%STMLStemline Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADROAduro BiotechN/AN/AN/AN/AN/AN/AN/AN/AAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALXRXLexicon Pharmaceuticals2.5345 of 5 stars3.23.00.00.01.42.50.6STMLStemline TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADROAduro Biotech 0.00N/AN/AN/AAMAGAMAG Pharmaceuticals 0.00N/AN/AN/AGEMPGemphire Therapeutics 0.00N/AN/AN/ALXRXLexicon Pharmaceuticals 2.40Hold$3.67302.93% UpsideSTMLStemline Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADRO, AMAG, LXRX, GEMP, and STML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADROAduro Biotech$17.26M0.00N/AN/A$4.07 per share0.00AMAGAMAG Pharmaceuticals$327.75M1.46N/AN/A$7.37 per share1.87GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/ALXRXLexicon Pharmaceuticals$31.08M10.58N/AN/A$0.40 per share2.28STMLStemline Therapeutics$43.22M14.37N/AN/A$3.26 per share3.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADROAduro Biotech-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/AAMAGAMAG Pharmaceuticals-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/AGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/ALXRXLexicon Pharmaceuticals-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%7/30/2025 (Estimated)STMLStemline Therapeutics-$76.82M-$1.83N/AN/AN/A-150.30%-48.14%-41.35%N/ALatest ADRO, AMAG, LXRX, GEMP, and STML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LXRXLexicon Pharmaceuticals-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADROAduro BiotechN/AN/AN/AN/AN/AAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ASTMLStemline TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADROAduro BiotechN/A8.918.91AMAGAMAG Pharmaceuticals1.131.751.45GEMPGemphire TherapeuticsN/A0.670.67LXRXLexicon Pharmaceuticals0.482.222.22STMLStemline TherapeuticsN/A7.437.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADROAduro Biotech49.93%AMAGAMAG PharmaceuticalsN/AGEMPGemphire Therapeutics17.53%LXRXLexicon Pharmaceuticals74.70%STMLStemline Therapeutics75.80%Insider OwnershipCompanyInsider OwnershipADROAduro Biotech5.90%AMAGAMAG Pharmaceuticals12.73%GEMPGemphire Therapeutics22.70%LXRXLexicon Pharmaceuticals13.90%STMLStemline Therapeutics11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADROAduro Biotech15216.21 millionN/AOptionableAMAGAMAG Pharmaceuticals44034.73 millionN/AOptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableLXRXLexicon Pharmaceuticals140361.49 million311.25 millionOptionableSTMLStemline Therapeutics9252.51 millionN/AOptionableADRO, AMAG, LXRX, GEMP, and STML HeadlinesRecent News About These CompaniesInsilico Medicine licenses 2nd AI-generated cancer drug candidate to Menarini’s Stemline in $550M dealJanuary 10, 2025 | fiercebiotech.comFMenarini bags blood cancer drug with $677M Stemline acquisitionAugust 5, 2024 | pharmaphorum.comPMenarini Group and Insilico Medicine Enter Global Exclusive License Agreement forJanuary 6, 2024 | newswire.caMenarini Group’s Stemline inks $500M+ biobucks deal for Insilico’s breast cancer candidateJanuary 4, 2024 | fiercebiotech.comFStemline Therapeutics describes new RET mutant inhibitors for cancerMay 6, 2023 | bioworld.comBNew Hormonal Treatment Orserdu Approved for Metastatic Breast CancerFebruary 19, 2023 | everydayhealth.comEStemline Therapeutics’ breast cancer treatment approvedFebruary 1, 2023 | labiotech.euLFDA Approves Stemline’s Orserdu for Several Forms of Breast CancerJanuary 31, 2023 | fdanews.comFStemline first to market with oral SERD for breast cancerJanuary 31, 2023 | pharmaphorum.comPTrade These 7 Stocks Under $10 for Huge ProfitsApril 10, 2022 | thestreet.comBreakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)October 26, 2021 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADRO, AMAG, LXRX, GEMP, and STML Company DescriptionsAduro Biotech NASDAQ:ADROChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.AMAG Pharmaceuticals NASDAQ:AMAGAMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.Gemphire Therapeutics NASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Lexicon Pharmaceuticals NASDAQ:LXRX$0.91 -0.01 (-0.64%) Closing price 07/3/2025 03:52 PM EasternExtended Trading$0.91 0.00 (0.00%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Stemline Therapeutics NASDAQ:STMLStemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.